Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intra-plaque vascularization assessed in contrast-enhanced ultrasound predicts cardiovascular events in type 2 diabetes with no significant carotid atherosclerotic stenosis: a prospective study with therapeutic implications for SGLT2 inhibitor use.

European heart journal. Imaging methods and practice·2025
Same author

A six-year longitudinal study identifies a statin-independent association between low LDL-cholesterol and risk of type 2 diabetes.

Cardiovascular diabetology·2025
Same author

GLP-1 Receptor Agonists Are Associated with Reduced Ascending Aorta Dilatation in Patients with Type 2 Diabetes: A Prospective Study.

International journal of molecular sciences·2025
Same author

Correction: Statin-induced risk of diabetes does not reduce cardiovascular benefits in primary prevention: a 6-year propensity-score matched study in a large population.

Cardiovascular diabetology·2025
Same author

Aspirin reduces the risk of type 2 diabetes associated with COVID-19.

npj metabolic health and disease..·2025
Same author

The COVID-19 pandemic increased the incidence of newly diagnosed cancers: evidence from a large cohort study in Southern Italy.

BMC medicine·2025
Same journal

Giornale italiano di cardiologia (2006)·2026
Same journal

[Green paper ANMCO: Environmental sustainability in cardiology: a shared commitment of healthcare professionals].

Giornale italiano di cardiologia (2006)·2026
Same journal

[Bempedoic acid in real-world clinical practice: baseline and 8-week data from the Italian prospective, non-interventional MILOS study].

Giornale italiano di cardiologia (2006)·2026
Same journal

[Ranolazine: established indications and emerging therapeutic potential].

Giornale italiano di cardiologia (2006)·2026
Same journal

[Kawasaki disease: the update of American Heart Association guidelines. What adult cardiologists need to know].

Giornale italiano di cardiologia (2006)·2026
Same journal

[The application of artificial intelligence in arrhythmology].

Giornale italiano di cardiologia (2006)·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

[Renin-angiotensin system modulation: instructions for use].

Alessandro Bellis1, Francesco Rozza, Salvatore Crispo

  • 1Dipartimento di Medicina Clinica, Scienze Cardiovascolari e Immunologiche, Università degli Studi Federico II, Napoli.

Giornale Italiano Di Cardiologia (2006)
|April 4, 2008
PubMed
Summary
This summary is machine-generated.

Angiotensin-converting enzyme (ACE) inhibitors and AT1 receptor blockers offer comparable cardiovascular benefits. However, AT1 blockers may be superior for early prevention of cardiovascular and renal diseases.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Experiment Videos

Last Updated: Jul 6, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Context:

  • ACE inhibitors and AT1 receptor blockers are mainstays in cardiovascular disease management.
  • Previous trials suggested comparable efficacy for both drug classes in hypertension, myocardial infarction, and heart failure.
  • Recent findings indicate potential synergistic effects when used in combination.

Purpose:

  • To re-evaluate the distinct mechanisms of action between ACE inhibitors and AT1 receptor blockers.
  • To explore the differential effects of these drug classes in early-stage cardiovascular and renal disease.
  • To assess the role of novel renin inhibitors in managing angiotensin II-mediated effects.

Summary:

  • While ACE inhibitors and AT1 receptor blockers were considered equivalent, combination therapy shows improved outcomes.
  • Pathophysiological studies suggest AT1 receptor blockers are effective in early intervention, improving cardiac function and preventing kidney damage.
  • AT1 receptor blockers may offer advantages over ACE inhibitors for early cardiovascular and renal protection.

Impact:

  • Suggests a potential shift in therapeutic strategy, favoring AT1 receptor blockers for early disease prevention.
  • Highlights the importance of understanding nuanced drug mechanisms beyond the renin-angiotensin-aldosterone system.
  • Opens avenues for novel therapeutic approaches involving renin inhibitors to mitigate angiotensin II escape.